Hedgehog Pathway Inhibitors Pipeline Insights, 2021

 What are Hedgehog Pathway Inhibitors?

Hedgehog pathway inhibitors are small molecules that inhibit the activity of a component of the Hedgehog signaling pathway. Due to the role of aberrant Hedgehog signaling in tumor progression and cancer stem cell maintenance across cancer types, inhibition of the Hedgehog signaling pathway is usually a useful strategy for restricting tumor growth and for preventing the recurrence of the disease post-surgery, or post-chemotherapy.

DelveInsight launched a new report on “Hedgehog Pathway Inhibitors - Pipeline Insight, 2021.’ The report provides comprehensive insights about key companies and pipeline drugs in Hedgehog Pathway Inhibitors pipeline landscape.

The report covers the pipeline drug profiles, including clinical and nonclinical stage products, therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products during this space.

Request for sample pages of the report: https://www.delveinsight.com/sample-request/hedgehog-pathway-inhibitors-pipeline-insight

Hedgehog Pathway Inhibitors Causes and Side Effects

Adverse events (AEs) commonly observed in hedgehog pathway inhibitor (HPI)-treated patients include muscle spasms, ageusia/dysgeusia, alopecia, weight loss, and asthenia (fatigue). These AEs are thought to be mechanistically associated with inhibition of the hedgehog pathway in normal tissue.

Hedgehog Pathway Inhibitors Market Key Insights

●       The total Hedgehog Pathway Inhibitors market size was USD XX million in 2018.

●       The Hedgehog Pathway Inhibitors market size shall increase during the forecast period (2018–2030) due to the launch of upcoming therapies.

●       The US accounted for XX% of the Hedgehog Pathway Inhibitors market size in 2018.

●       The Hedgehog Pathway Inhibitors market size was USD XX million in 2018.

According to DelveInsight, the Hedgehog Pathway Inhibitors Market in 7MM is expected to change.

Got queries? Click here to get insights into Hedgehog Pathway Inhibitors Pipeline Insights

Hedgehog Pathway Inhibitors Emerging Therapy Assessment

The plethora of kinase inhibitors is currently in Phase II and Phase III stage of clinical development for various indications. Some of the major key pharma players include: 

  1. NLM-001 by Nelum Pharmaceuticals
  2. Patigetib by PellePharm
  3. SUBA-itraconazole by Mayne Pharma
  4. IMP5471 by Impact Therapeutics

The emerging therapy assessment segment of the Hedgehog Pathway Inhibitors report encloses an in-depth analysis of Hedgehog Pathway Inhibitors marketed drugs and late-stage pipeline drugs.

Comments

Post a Comment

Popular posts from this blog

Beta-thalassemia Market Poised for Significant Growth with Novel Therapies and Rising Prevalence

The Beta-thalassemia market is set to experience remarkable growth in the coming years, driven by the increasing prevalence of the condition and the anticipated launch of innovative therapies. Leading players in the pharmaceutical and biotech industries, including Acceleron Pharma, Agios Pharmaceuticals, Bluebird Bio, and CRISPR Therapeutics, are working diligently to address unmet medical needs and expand treatment options. Download our sample pages @ https://www.delveinsight.com/report-store/beta-thalassemia-market?utm_source=report&utm_medium=promotion&utm_campaign=kpr Market Dynamics and Key Drivers Beta-thalassemia, a hereditary blood disorder caused by mutations in the HBB gene, results in reduced or absent synthesis of beta-globin chains in hemoglobin. This condition affects millions worldwide, with significant prevalence in regions such as the United States, Europe, and Asia. Recent advancements in diagnostics and a heightened focus on genetic counseling have contribute...
Read more

Growth of the Candidemia Market: Drivers, Developments, and Future Outlook (2024-2034)

Candidemia , a bloodstream infection caused by Candida species, poses significant health challenges, particularly among individuals with weakened immune systems. The global candidemia market is projected to experience a compound annual growth rate (CAGR) of 3.16% from 2024 to 2034. citeturn0search0 Market Drivers: Increasing Incidence: The rising number of immunocompromised patients, including those with HIV/AIDS, cancer, or organ transplants, has led to a higher prevalence of candidemia. Advancements in Diagnostics: The adoption of advanced diagnostic techniques, such as molecular assays and biomarker identification, facilitates swift and accurate detection of candidemia, enabling timely intervention and improved patient outcomes. Innovative Therapeutics: The development of novel antifungal medications and immune-based therapies offers enhanced efficacy and reduced adverse effects, contributing to market growth. To know more about candidemia market drivers, visit https://www.delvei...
Read more

Unlocking the Facts: C-Met Mutated Non-Small Cell Lung Cancer Epidemiology, Market Trends, and Leading Players

What is C-Met Mutated Non-small Cell Lung Cancer ? C-Met (also known as MET) is a gene that codes for a protein called the "hepatocyte growth factor receptor" (HGFR) or c-Met receptor. This receptor plays a crucial role in regulating cell growth, survival, migration, and invasion. When the c-Met gene is mutated, it can lead to the abnormal activation of signaling pathways that promote cancer development and progression. How is C-Met Mutated Non-small Cell Lung Cancer epidemiology segmented? C-Met Mutated Non-small Cell Lung Cancer epidemiology is segmented as C-Met Mutated Non-small Cell Lung Cancer Total Incident Cases, Age-specific C-Met Mutated Non-small Cell Lung Cancer cases, Gender-specific C-Met Mutated Non-small Cell Lung Cancer Cases, Stage-specific C-Met Mutated Non-small Cell Lung Cancer incident cases, Type-specific C-Met Mutated Non-small Cell Lung Cancer incident cases, and Total Treated C-Met Mutated Non-small Cell Lung Cancer Cases. What is the C-Met Mutated...
Read more